Search Result

Results for "

bacterial topoisomerases

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Bacterial (72) Akt (1) AMPK (1) Antibiotic (42) Apoptosis (8) Checkpoint Kinase (Chk) (1) Cholinesterase (ChE) (1) DNA Glycosylase (1) DNA/RNA Synthesis (26) Endogenous Metabolite (1) Fungal (2) HIF/HIF Prolyl-Hydroxylase (1) Interleukin Related (3) Isotope-Labeled Compounds (6) MicroRNA (5) mTOR (1) NF-κB (1) Orthopoxvirus (2) p38 MAPK (1) Reactive Oxygen Species (ROS) (3) Reference Standards (13) Topoisomerase (58) β-catenin (2)
By Research Areas:	Cancer (14) Endocrinology (2) Infection (77) Inflammation/Immunology (11) Metabolic Disease (1) Neurological Disease (3)

By Targets:

Bacterial (72)

Akt (1)

AMPK (1)

Antibiotic (42)

Apoptosis (8)

Checkpoint Kinase (Chk) (1)

Cholinesterase (ChE) (1)

DNA Glycosylase (1)

DNA/RNA Synthesis (26)

Endogenous Metabolite (1)

Fungal (2)

HIF/HIF Prolyl-Hydroxylase (1)

Interleukin Related (3)

Isotope-Labeled Compounds (6)

MicroRNA (5)

mTOR (1)

NF-κB (1)

Orthopoxvirus (2)

p38 MAPK (1)

Reactive Oxygen Species (ROS) (3)

Reference Standards (13)

Topoisomerase (58)

β-catenin (2)

By Research Areas:

Cancer (14)

Endocrinology (2)

Infection (77)

Inflammation/Immunology (11)

Metabolic Disease (1)

Neurological Disease (3)

Inhibitors & Agonists

Fluorescent Dyes

Biochemical Assay Reagents

Natural
Products

Isotope-Labeled Compounds

GMP Molecules

Targets Recommended: Bacterial

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-16742

Gepotidacin 10+ Cited Publications GSK2140944	Antibiotic Bacterial Topoisomerase	Infection
Gepotidacin (GSK2140944) is a novel triazaacenaphthylene bacterial type II *topoisomerase* inhibitor.

HY-17028

Besifloxacin Hydrochloride	Bacterial Antibiotic DNA/RNA Synthesis Topoisomerase	Infection Inflammation/Immunology
Besifloxacin Hydrochloride is a fourth generation fluoroquinolone antibiotic. Besifloxacin Hydrochloride is a DNA gyrase and topoisomerase IV inhibitor. Besifloxacin Hydrochloride has broad-spectrum antibacterial activity, it is effective against Gram-negative and Gram-positive aerobic and anaerobic strains and reduces the incidence of drug resistance. Besifloxacin Hydrochloride has anti-inflammatory activity. Besifloxacin Hydrochloride can be used in bacterial conjunctivitis research .

HY-10581

Gatifloxacin 4 Publications Verification AM-1155; BMS-206584; PD135432	Bacterial Topoisomerase Antibiotic	Infection Neurological Disease Cancer
Gatifloxacin (AM-1155; BMS-206584; PD135432) is a potent fluoroquinolone antibiotic that can cross the blood-brain barrier, with broad-spectrum antibacterial activity. Gatifloxacin inhibits bacterial type II topoisomerases (IC₅₀=13.8 μg/ml for S. aureus topoisomerase IV) and E. coli DNA gyrase (IC₅₀=0.109 μg/ml) . Gatifloxacin can be used to treat bacterial conjunctivitis in vivo.

HY-B0330D

(R)-Ofloxacin 1 Publications Verification Dextrofloxacin	Bacterial Antibiotic	Infection
(R)-Ofloxacin is the dextrorotatory enantiomer of Ofloxacin (HY-B0125) and is an orally effective fluoroquinolone antibiotic. (R)-Ofloxacin can inhibit the activity of bacterial DNA topoisomerase II, interfere with bacterial DNA replication and repair, and exert a bactericidal effect. (R)-Ofloxacin has a broad-spectrum antibacterial activity and has inhibitory effects on both Gram-negative and Gram-positive bacteria .

HY-17647

Zoliflodacin 5+ Cited Publications ETX0914; AZD0914	DNA/RNA Synthesis Bacterial Antibiotic	Infection
Zoliflodacin (ETX0914;AZD0914) is a novel spiropyrimidinetrione **bacterial DNA gyrase/topoisomerase** inhibitor. Zoliflodacin has potent in vitro antibacterial activity against Gram-positive and Gram-negative organisms, including S. aureus with the MIC₉₀ of 0.25 μg/mL.

HY-B0455

Lomefloxacin hydrochloride SC47111A hydrochloride; NY-198 hydrochloride	Antibiotic Bacterial Topoisomerase Reactive Oxygen Species (ROS) Apoptosis	Infection Endocrinology Cancer
Lomefloxacin hydrochloride (NY-198 hydrochloride) is an orally active difluoroquinolone antibiotic. Lomefloxacin hydrochloride prevents DNA supercoiling and replication by inhibiting bacterial topoisomerase II. Lomefloxacin hydrochloride induces ROS production and Apoptosis. Lomefloxacin hydrochloride has broad-spectrum bactericidal activity against Gram-positive and Gram-negative bacteria. Lomefloxacin hydrochloride has anticancer effects against melanoma. Lomefloxacin hydrochloride can be used in the study of systemic bacterial infections (such as Salmonella typhimurium infections), skin and melanoma .

HY-B0506

Nadifloxacin 1 Publications Verification OPC7251	Bacterial Antibiotic DNA/RNA Synthesis Interleukin Related	Infection Inflammation/Immunology
Nadifloxacin (OPC7251) is a broad-spectrum quinolone antibiotic. Nadifloxacin inhibits bacterial DNA gyrase and topoisomerase IV, interfering with DNA replication. It also suppresses the production of proinflammatory cytokines (such as IL-1α, IL-6, and IL-8). Nadifloxacin exhibits antibacterial activity against various pathogens, including Propionibacterium acnes and Staphylococcus aureus. Nadifloxacin also exhibits anti-inflammatory activity. Nadifloxacin can be used in the research of skin infections such as acne vulgaris, folliculitis, and impetigo .

HY-Y0191

α-Pyridone 2-Pyridone	Endogenous Metabolite Bacterial	Infection
α-Pyridone (2-Pyridone) is an antibacterial agent that plays an important role in the field of biochemical research. α-Pyridone can serve as a scaffold compound to synthesize a variety of active compounds .

HY-B0268A

Enoxacin hydrate 2 Publications Verification Enoxacin sesquihydrate; AT-2266 hydrate; CI-919 hydrate	Bacterial DNA/RNA Synthesis MicroRNA Antibiotic	Infection Cancer
Enoxacin hydrate (Enoxacin sesquihydrate), a fluoroquinolone, interferes with DNA replication and inhibits bacterial DNA gyrase (IC₅₀=126 µg/ml) and topoisomerase IV (IC₅₀=26.5 µg/ml). Enoxacin hydrate is a miRNA processing activator and enhances siRNA-mediated mRNA degradation and promotes the biogenesis of endogenous miRNAs. Enoxacin hydrate has potent activities against gram-positive and -negative bacteria. Enoxacin hydrate is a cancer-specific growth inhibitor that acts by enhancing TAR RNA-binding protein 2 (TRBP)-mediated microRNA processing .

HY-B0268

Enoxacin 2 Publications Verification AT 2266; CI 919	Bacterial DNA/RNA Synthesis MicroRNA Antibiotic	Infection Cancer
Enoxacin (AT 2266), a fluoroquinolone, interferes with DNA replication and inhibits bacterial DNA gyrase (IC₅₀=126 µg/ml) and topoisomerase IV (IC₅₀=26.5 µg/ml). Enoxacin is a miRNA processing activator and enhances siRNA-mediated mRNA degradation and promotes the biogenesis of endogenous miRNAs. Enoxacin has potent activities against gram-positive and -negative bacteria. Enoxacin is a cancer-specific growth inhibitor that acts by enhancing TAR RNA-binding protein 2 (TRBP)-mediated microRNA processing .

HY-B0330B

Levofloxacin hydrochloride Maximum Cited Publications 35 Publications Verification (-)-Ofloxacin hydrochloride	Antibiotic Bacterial DNA/RNA Synthesis Topoisomerase Orthopoxvirus Apoptosis	Infection Neurological Disease Cancer
Levofloxacin hydrochloride is an orally active antibiotic. Levofloxacin inhibits DNA gyrase and topoisomerase IV activity, inducing Apoptosis. Levofloxacin hydrochloride has antibacterial activity against both Gram-positive and Gram-negative bacteria. Levofloxacin hydrochloride exhibits anticancer activity against lung cancer. Levofloxacin hydrochloride has anti-acnegenic, anxiogenic, and analgesic effects. Levofloxacin hydrochloride shortens sleep duration in mice. Levofloxacin hydrochloride can be used in the research of infectious diseases (such as tuberculosis, chronic periodontitis, bacterial infections associated with stable COPD, and BK viremia) and lung cancer .

HY-N7066

Difloxacin hydrochloride A-56619 hydrochloride	Bacterial DNA/RNA Synthesis	Infection
Difloxacin hydrochloride (A-56619 hydrochloride) is an orally active bactericidal agent. Difloxacin hydrochloride inhibits bacterial DNA gyrase. Difloxacin hydrochloride exhibits concentration-dependent bactericidal activity. Difloxacin hydrochloride shows strong in vitro activity against a variety of Gram-positive and Gram-negative bacteria. Difloxacin hydrochloride can be used in research related to colibacillosis and Staphylococcus aureus infections .

HY-10581A

Gatifloxacin hydrochloride 4 Publications Verification AM-1155 hydrochloride; BMS-206584 hydrochloride; PD135432 hydrochloride	Bacterial Topoisomerase Antibiotic	Infection
Gatifloxacin hydrochloride (AM-1155; BMS-206584; PD135432) is a potent fluoroquinolone antibiotic with broad-spectrum antibacterial activity. Gatifloxacin hydrochloride inhibits bacterial type II topoisomerases (IC₅₀=13.8 μg/ml for S. aureus topoisomerase IV) and E. coli DNA gyrase (IC₅₀ = 0.109 μg/ml) . Gatifloxacin hydrochloride can be used to treat bacterial conjunctivitis in vivo.

HY-N2198

Podocarpusflavone A	Fungal Bacterial Topoisomerase Apoptosis	Infection Inflammation/Immunology Cancer
Podocarpusflavone A is a biflavonoid present in the leaves of Podocarpus henkelii, with anti-tumor, topoisomerase I inhibitory, antibacterial and antifungal activities. Podocarpusflavone A exhibits antibacterial activity against Enterococcus faecalis and Pseudomonas aeruginosa. Podocarpusflavone A shows weak activity against fungal pathogens. Podocarpusflavone A targets topoisomerase I and induces cell cycle arrest and apoptosis in MCF-7 cells. Podocarpusflavone A can be used for studies on cancer, bacterial and fungal infections .

HY-B0455A

Lomefloxacin SC47111A; NY-198	Bacterial Antibiotic Topoisomerase Reactive Oxygen Species (ROS) Apoptosis	Infection
Lomefloxacin (SC47111A) is an orally active difluoroquinolone antibiotic. Lomefloxacin prevents DNA supercoiling and replication by inhibiting bacterial topoisomerase II. Lomefloxacin induces ROS production and Apoptosis. Lomefloxacin has broad-spectrum bactericidal activity against Gram-positive and Gram-negative bacteria. Lomefloxacin has anticancer effects against melanoma. Lomefloxacin can be used in the study of systemic bacterial infections (such as Salmonella typhimurium infections), skin and melanoma .

HY-16742B

Gepotidacin mesylate hydrate 10+ Cited Publications	Antibiotic Bacterial Topoisomerase	Infection
Gepotidacin mesylate hydrate is an orally active triazaacenaphthylene antibiotic and bacterial type II topoisomerase inhibitor. Gepotidacin mesylate hydrate inhibits bacterial DNA replication by blocking topoisomerase enzymes. Gepotidacin mesylate hydrate selectively inhibits topoisomerase IV and the B subunit of DNA gyrase .

HY-162959

BWC0977	Bacterial Topoisomerase DNA/RNA Synthesis	Infection
BWC0977 is an antibacterial agent that inhibits bacterial DNA replication via inhibition of DNA gyrase and topoisomerase IV. BWC0977 exhibits a minimum inhibitory concentration (MIC₉₀) of 0.03-2 µg/mL against MDR (Multi-Drug Resistant) Gram-negative bacteria .

HY-106410A

Zabofloxacin hydrochloride DW-224a	Bacterial Topoisomerase Antibiotic	Infection
Zabofloxacin hydrochloride (DW-224a) is a potent and seletive inhibitor of the **bacterial type II and IV topoisomerases*. Zabofloxacin hydrochloride has excellent activity against gram-positive pathogens including Steptococcus aureus, Streptococcus pyogenes* and S.pneumonia. Zabofloxacin hydrochloride is a novel fluoronaphthyridone quinolone that is considered as an alternative antibiotic for treatment of quinolone-susceptible (QSSP) and quinolone-resistant gonorrhea (QRSP) .

HY-W087058

1,4-Di-tert-butylbenzene	Topoisomerase	Infection
1,4-Di-tert-butylbenzene is a volatile compound identified in the hexane extracts of corn cob and green millet. 1,4-Di-tert-butylbenzene shows potent inhibition against receptor proteins of **Bacterial type II topoisomerase (4PLB and LpxC**) in docking analysis .

HY-12888

AZD5099	Topoisomerase Bacterial	Infection
AZD5099, an antibacterial agent, is a potent and selective bacterial topoisomerase II inhibitor. AZD5099 potently inhibits the infections caused by Gram-positive and fastidious Gram-negative bacteria .

HY-106410

Zabofloxacin DW-224a Free base	Bacterial Topoisomerase Antibiotic	Infection
Zabofloxacin (DW-224a Free base) is a potent and seletive inhibitor of the **bacterial type II and IV topoisomerases*. Zabofloxacin has excellent activity against gram-positive pathogens including Steptococcus aureus, Streptococcus pyogenes* and S.pneumonia. Zabofloxacin is a novel fluoronaphthyridone quinolone that is considered as an alternative antibiotic for treatment of quinolone-susceptible (QSSP) and quinolone-resistant gonorrhea (QRSP) .

HY-B0330BR

Levofloxacin hydrochloride (Standard) (-)-Ofloxacin hydrochloride (Standard)	Reference Standards Antibiotic Bacterial DNA/RNA Synthesis Topoisomerase Orthopoxvirus Apoptosis	Infection Neurological Disease Cancer
Levofloxacin (hydrochloride) (Standard) is the analytical standard of Levofloxacin hydrochloride (HY-B0330B). This product is intended for research and analytical applications. Levofloxacin hydrochloride is an orally active antibiotic. Levofloxacin inhibits DNA gyrase and topoisomerase IV activity, inducing Apoptosis. Levofloxacin hydrochloride has antibacterial activity against both Gram-positive and Gram-negative bacteria. Levofloxacin hydrochloride exhibits anticancer activity against lung cancer. Levofloxacin hydrochloride has anti-acnegenic, anxiogenic, and analgesic effects. Levofloxacin hydrochloride shortens sleep duration in mice. Levofloxacin hydrochloride can be used in the research of infectious diseases (such as tuberculosis, chronic periodontitis, bacterial infections associated with stable COPD, and BK viremia) and lung cancer .

HY-16742C

Gepotidacin hydrochloride GSK2140944 hydrochloride	Antibiotic Bacterial Topoisomerase	Infection
Gepotidacin hydrochloride is a novel triazaacenaphthylene bacterial type II *topoisomerase* inhibitor.

HY-173478

OSUAB-0284	Topoisomerase Bacterial Antibiotic	Infection
OSUAB-0284 is a **bacterial topoisomerase** inhibitor. OSUAB-0284 has significant anti-staphylococcal activity, especially against methicillin-resistant Staphylococcus aureus (MRSA). OSUAB-0284 exerts its antibacterial effect by inhibiting bacterial topoisomerase. OSUAB-0284 can be used to study infections caused by drug-resistant bacteria such as MRSA .

HY-10581C

Gatifloxacin sesquihydrate AM-1155 sesquihydrate; BMS-206584 sesquihydrate; PD135432 sesquihydrate	Bacterial Topoisomerase Antibiotic	Infection Inflammation/Immunology
Gatifloxacin sesquihydrate (AM-1155; BMS-206584; PD135432) is a potent fluoroquinolone antibiotic with broad-spectrum antibacterial activity. Gatifloxacin sesquihydrate inhibits bacterial type II topoisomerases (IC₅₀=13.8 μg/ml for S. aureus topoisomerase IV) and E. coli DNA gyrase (IC₅₀ = 0.109 μg/ml) . Gatifloxacin sesquihydrate can be used to treat bacterial conjunctivitis in vivo.

HY-16742R

Gepotidacin (Standard) GSK2140944 (Standard)	Reference Standards Antibiotic Bacterial Topoisomerase	Infection
Gepotidacin (Standard) is the analytical standard of Gepotidacin. This product is intended for research and analytical applications. Gepotidacin (GSK2140944) is a novel triazaacenaphthylene bacterial type II topoisomerase inhibitor.

HY-115990

Topoisomerase IV inhibitor 1	Topoisomerase Bacterial	Infection
Topoisomerase IV inhibitor 2 (compound 7d) is a potent *DNA topoisomerase* IV (TOPO IV) inhibitor with IC₅₀*s of 0.23 μM and 0.43 μM for TOPO* IV and DNA gyrase, respectively. Topoisomerase IV inhibitor 2 has anti-bacterial activity, with MICs of 0.972 μM and 0.608 μM in Staphylococcus aureus Newman and Escherichia coli ATCC8739, respectively .

HY-162959A

BWC0977 formic	Bacterial Topoisomerase DNA/RNA Synthesis	Infection
BWC0977 formic is an antibacterial agent that inhibits bacterial DNA replication via inhibition of DNA gyrase and topoisomerase IV. BWC0977 formic exhibits a minimum inhibitory concentration (MIC₉₀) of 0.03-2 µg/mL against MDR (Multi-Drug Resistant) Gram-negative bacteria .

HY-B0268S1

Enoxacin-d8 hydrochloride	Isotope-Labeled Compounds Bacterial DNA/RNA Synthesis MicroRNA Antibiotic	Infection Cancer
Enoxacin-d₈ (hydrochloride) is deuterium labeled Enoxacin. Enoxacin (AT 2266), a fluoroquinolone, interferes with DNA replication and inhibits bacterial DNA gyrase (IC₅₀=126 μg/ml) and topoisomerase IV (IC₅₀=26.5 μg/ml). Enoxacin is a miRNA processing activator and enhances siRNA-mediated mRNA degradation and promotes the biogenesis of endogenous miRNAs. Enoxacin has potent activities against gram-positive and -negative bacteria. Enoxacin is a cancer-specific growth inhibitor that acts by enhancing TAR RNA-binding protein 2 (TRBP)-mediated microRNA processing .

HY-175539

DNA gyrase/Topo IV-IN-2	Bacterial Topoisomerase DNA/RNA Synthesis	Infection
DNA gyrase/Topo IV-IN-2 (Compound AK19) is an antibacterial agent with IC₅₀ values of 0.783 μM and 7.136 μM against E. coli DNA gyrase and topoisomerase IV, respectively. DNA gyrase/Topo IV-IN-2 exhibits broad-spectrum antibacterial efficacy against both Gram-positive and Gram-negative pathogens. DNA gyrase/Topo IV-IN-2 can inhibit the biofilms of B. subtilis and MRSA, with an MIC of 1.9 μM against both B. subtilis and MRSA. DNA gyrase/Topo IV-IN-2 can be used in research related to anti-drug-resistant bacterial drugs .

HY-173458

NBTIs-IN-7	Topoisomerase	Infection
NBTIs-IN-7 (compound 276) is a *novel bacterial* topoisomerase (NBTIs)** inhibitor. NBTIs-IN-7 induces both single- and double-strand DNA strand breaks in the presence of gyrase .

HY-174227

Topoisomerase inhibitor 6	Topoisomerase Bacterial	Infection
Topoisomerase inhibitor 6 (Compound REDX05931) is a dual irreversible inhibitor of DNA gyrase and topoisomerase IV (MIC=0.06 μg/mL against fluoroquinolone-resistant S. aureus). Topoisomerase inhibitor 6 blocks DNA strand break-reunion, inducing lethal DNA damage. Topoisomerase inhibitor 6 is promising for research of Gram-positive bacterial infections (e.g., S. aureus, S. pneumoniae) .

HY-143483

NBTIs-IN-5	Bacterial	Infection
NBTIs-IN-5 (Compound 5r) is a NBTI (Novel Bacterial Topoisomerase Inhibitor) DNA gyrase inhibitor with an IC₅₀ of 1.5 μM against Mycobacterium abscessus (Mabs) DNA gyrase. NBTIs-IN-5 inhibits Mabs bamboo bacterial growth with an MIC₉₀ of 0.4 μM .

HY-143484

844-TFM	Bacterial	Infection
844-TFM is a NBTI (novel bacterial topoisomerase inhibitor) DNA gyrase inhibitor, with an IC₅₀ of 1.5 μM. 844-TFM exhibits bactericidal properties against M. abscessus .

HY-B0013

Lavofloxacin lactate (-)-Ofloxacin lactate	Bacterial DNA/RNA Synthesis	Infection
Lavofloxacin lactate ((-)-ofloxacin lactate) is a class of broad-spectrum antimicrobials that can kill or inhibit a variety of bacteria. Lavofloxacin lactate binds to DNA rotase and topoisomerase IV, resulting in blocked DNA replication and repair, thus inhibiting bacterial growth. Lavofloxacin lactate can be used to study resistance mechanisms in bacteria, including studying resistance genes and mutations .

HY-172229

NBTI 5463	Topoisomerase Bacterial	Infection
NBTI 5463 is a bacterial type II topoisomerases (topoisomerase II) inhibitor with antibacterial activity. NBTI 5463 inhibits GyrA and TopoIV in Pseudomonas aeruginosa and Escherichia coli. NBTI 5463 binds to topoisomerase II to prevent DNA cleavage and religation, inhibiting bacterial DNA replication and transcription. NBTI 5463 is promising for research of Gram-negative bacterial infection .

HY-168849

Topoisomerase inhibitor 5	Topoisomerase Bacterial	Infection
Topoisomerase inhibitor 5 (compound 158) is a Bacterial Topoisomerase Inhibitor inhibitor with the lowest inhibitory concentration of 0.125 μg/mL. Topoisomerase inhibitor has antituberculous activity .

HY-123589

Gyramide A	Bacterial	Others
Gyramide A is a compound mentioned in the study of the protective effect of Qnr protein on bacterial topoisomerase. Qnr has no protective effect on it, and its activity is different from that of other topoisomerase inhibitors.

HY-178738

GC-072	Antibiotic Bacterial Topoisomerase DNA/RNA Synthesis	Infection
GC-072 is an orally active, 4-oxoquinolizine antibiotic that selectively inhibits bacterial DNA gyrase and Topo IV enzymes. GC-072 does not inhibit human topoisomerases I and II. GC-072 demonstrates strong antimicrobial activity against various bacterial strains, including Gram-positive, Gram-negative, and resistant bacteria. GC-072 also exhibits bactericidal activity against Burkholderia pseudomallei both extracellularly and intracellularly, leading to dose-dependent survival in mice exposed to lethal inhalational models of B. pseudomallei infection. GC-072 can be used for the research of melioidosis .

HY-161980

Topoisomerases/ribosomes-IN-1	Topoisomerase	Infection
Topoisomerases/ribosomes-IN-1 (compound 30f) is an inhibitor of ribosomes and *topoisomerases, and has inhibitory effects on constitutively macrolide-resistant bacteria. Topoisomerases/ribosomes-IN-1 can inhibit bacterial* protein synthesis (IC₅₀: 0.647 μM) and DNA replication (IC₅₀: 0.218 μM) .

HY-10581B

Gatifloxacin mesylate AM-1155 mesylate; BMS-206584 mesylate; PD135432 mesylate	Bacterial Topoisomerase Antibiotic	Infection
Gatifloxacin mesylate (AM-1155; BMS-206584; PD135432) is a potent fluoroquinolone antibiotic with broad-spectrum antibacterial activity. Gatifloxacin mesylate inhibits bacterial type II topoisomerases (IC₅₀=13.8 μg/ml for S. aureus topoisomerase IV) and E. coli DNA gyrase (IC₅₀ = 0.109 μg/ml) . Gatifloxacin mesylate can be used to treat bacterial conjunctivitis in vivo.

HY-146816

NBTIs-IN-6	Topoisomerase	Infection
NBTIs-IN-6 is a bacterial topoisomerase inhibitor with certain antibacterial activity. Among them, the MIC₉₀ for fluoroquinolone-resistant MRSA was 2 μg/mL .

HY-149309

Topoisomerase inhibitor 2	Topoisomerase	Infection
Topoisomerase inhibitor 2 (18C) is a bacterial topoisomeraseinhibitor that exhibits potent broad-spectrum activity against multidrug-resistant Gram-negative bacteria .

HY-10581AS

Gatifloxacin-d3 hydrochloride AM-1155-d3 hydrochloride; BMS-206584-d3 hydrochloride; PD135432-d3 hydrochloride	Isotope-Labeled Compounds Bacterial Topoisomerase Antibiotic	Infection
Gatifloxacin-d₃ (hydrochloride) is the deuterium labeled Gatifloxacin (hydrochloride). Gatifloxacin hydrochloride (AM-1155; BMS-206584; PD135432) is a potent fluoroquinolone antibiotic with broad-spectrum antibacterial activity. Gatifloxacin hydrochloride inhibits bacterial type II topoisomerases (IC50=13.8 μg/ml for S. aureus topoisomerase IV) and E. coli DNA gyrase (IC50 = 0.109 μg/ml). Gatifloxacin hydrochloride can be used to treat bacterial conjunctivitis in vivo.

HY-10581AR

Gatifloxacin hydrochloride (Standard) AM-1155 hydrochloride (Standard); BMS-206584 hydrochloride (Standard); PD135432 hydrochloride (Standard)	Reference Standards Bacterial Topoisomerase Antibiotic	Infection
Gatifloxacin (hydrochloride) (Standard) is the analytical standard of Gatifloxacin (hydrochloride). This product is intended for research and analytical applications. Gatifloxacin hydrochloride (AM-1155; BMS-206584; PD135432) is a potent fluoroquinolone antibiotic with broad-spectrum antibacterial activity. Gatifloxacin hydrochloride inhibits bacterial type II topoisomerases (IC50=13.8 μg/ml for S. aureus topoisomerase IV) and E. coli DNA gyrase (IC50 = 0.109 μg/ml)[1]. Gatifloxacin hydrochloride can be used to treat bacterial conjunctivitis in vivo.

HY-115991

Topoisomerase IV inhibitor 2	Topoisomerase Bacterial	Infection
Topoisomerase IV inhibitor 2 (compound 5d) is a potent *DNA topoisomerase* IV (TOPO IV) inhibitor with IC₅₀*s of 0.35 μM and 0.55 μM for TOPO* IV and DNA gyrase, respectively. Topoisomerase IV inhibitor 2 has anti-bacterial activity, with MICs of 1.985 μM and 0.744 μM in Staphylococcus aureus Newman and Escherichia coli ATCC8739, respectively .

HY-W700069

Gatifloxacin-d4 AM-1155-d₄; BMS-206584-d₄; PD135432-d₄	Isotope-Labeled Compounds Antibiotic Bacterial Topoisomerase	Infection
Gatifloxacin-d₄ (AM-1155-d₄) is the deuterium labeled Gatifloxacin (HY-10581). Gatifloxacin (AM-1155; BMS-206584; PD135432) is a potent fluoroquinolone antibiotic with broad-spectrum antibacterial activity. Gatifloxacin inhibits bacterial type II topoisomerases (IC₅₀ = 13.8 μg/mL for S. aureus topoisomerase IV) and E.coli DNA gyrase (IC₅₀ = 0.109 μg/mL) . Gatifloxacin can be used for the study of bacterial conjunctivitis in vivo.

HY-10581R

Gatifloxacin (Standard) AM-1155 (Standard); BMS-206584 (Standard); PD135432 (Standard)	Reference Standards Bacterial Topoisomerase Antibiotic	Infection
Gatifloxacin (Standard) is the analytical standard of Gatifloxacin. This product is intended for research and analytical applications. Gatifloxacin (AM-1155; BMS-206584; PD135432) is a potent fluoroquinolone antibiotic with broad-spectrum antibacterial activity. Gatifloxacin inhibits bacterial type II topoisomerases (IC₅₀=13.8 μg/ml for S. aureus topoisomerase IV) and E. coli DNA gyrase (IC₅₀=0.109 μg/ml) . Gatifloxacin can be used to treat bacterial conjunctivitis in vivo.

HY-10581CR

Gatifloxacin sesquihydrate (Standard) AM-1155 sesquihydrate (Standard); BMS-206584 sesquihydrate (Standard); PD135432 sesquihydrate (Standard)	Reference Standards Bacterial Topoisomerase Antibiotic	Infection Inflammation/Immunology
Gatifloxacin (sesquihydrate) (Standard) is the analytical standard of Gatifloxacin (sesquihydrate). This product is intended for research and analytical applications. Gatifloxacin sesquihydrate (AM-1155; BMS-206584; PD135432) is a potent fluoroquinolone antibiotic with broad-spectrum antibacterial activity. Gatifloxacin sesquihydrate inhibits bacterial type II topoisomerases (IC50=13.8 μg/ml for S. aureus topoisomerase IV) and E. coli DNA gyrase (IC50 = 0.109 μg/ml) . Gatifloxacin sesquihydrate can be used to treat bacterial conjunctivitis?in vivo.

HY-147729

UIAA-II-232	DNA/RNA Synthesis	Infection
UIAA-II-232 (compound 19b) is a potent DNA gyrase catalytic inhibitor with an IC₅₀ value of 3.5 µM .

Cat. No.	Product Name	Type

HY-B0356G

Ciprofloxacin

Bay-09867

Fluorescent Dyes

Ciprofloxacin GMP is Ciprofloxacin (HY-B0356) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Ciprofloxacin (Bay-09867) is an orally active, blood-brain barrier permeable fluoroquinolone antibacterial agent. Ciprofloxacin exerts bactericidal effects primarily by inhibiting topoisomerase II and IV. Ciprofloxacin inhibits the proliferation of human dental pulp stem cells and chondrocytes from young rats, and also activates the Akt signaling pathway and upregulates markers such as β-catenin and Nanog to maintain the morphological characteristics of stem cells. Ciprofloxacin induces significant neurotoxicity and tissue damage, including reducing serotonin and glutathione levels in the brain, inducing oxidative stress and depression-like behaviors, and causing articular cartilage damage. Ciprofloxacin can be applied to research related to infections of necrotic young permanent teeth and neurotoxicity .

Cat. No.	Product Name	Type

HY-W353258R

Moxifloxacin hydrochloride monohydrate (Standard)

BAY 12-8039 monohydrate (Standard)

Biochemical Assay Reagents

Moxifloxacin hydrochloride (BAY 12-8039) monohydrate (Standard) is the analytical standard of Moxifloxacin hydrochloride monohydrate. This product is intended for research and analytical applications. Moxifloxacin hydrochloride monohydrate is a blood-brain barrier-permeable, orally active topoisomerase II/IV inhibitor and a fluoroquinolone antibiotic. Moxifloxacin hydrochloride monohydrate disrupts bacterial DNA replication, transcription, repair and chromosome segregation processes. Moxifloxacin hydrochloride monohydrate exhibits activity against Gram-positive bacteria, Gram-negative bacteria, anaerobes, atypical pathogens, drug-resistant respiratory pathogens, Mycobacterium tuberculosis, mycoplasmas and Ureaplasma urealyticum.

HY-B0356G

Ciprofloxacin

Bay-09867

Biochemical Assay Reagents

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-Y0191

α-Pyridone 2-Pyridone	Structural Classification Natural Products Classification of Application Fields Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite Bacterial
α-Pyridone (2-Pyridone) is an antibacterial agent that plays an important role in the field of biochemical research. α-Pyridone can serve as a scaffold compound to synthesize a variety of active compounds .

HY-N2198

Podocarpusflavone A	Structural Classification Flavonoids Classification of Application Fields Guttiferae Phenols Polyphenols Plants Garcinia subelliptica Biflavones Disease Research Fields Source Classification Cancer	Fungal Bacterial Topoisomerase Apoptosis
Podocarpusflavone A is a biflavonoid present in the leaves of Podocarpus henkelii, with anti-tumor, topoisomerase I inhibitory, antibacterial and antifungal activities. Podocarpusflavone A exhibits antibacterial activity against Enterococcus faecalis and Pseudomonas aeruginosa. Podocarpusflavone A shows weak activity against fungal pathogens. Podocarpusflavone A targets topoisomerase I and induces cell cycle arrest and apoptosis in MCF-7 cells. Podocarpusflavone A can be used for studies on cancer, bacterial and fungal infections .

HY-123589

Gyramide A	Alkaloids Microorganisms Pyrrole Alkaloids Source Classification	Bacterial
Gyramide A is a compound mentioned in the study of the protective effect of Qnr protein on bacterial topoisomerase. Qnr has no protective effect on it, and its activity is different from that of other topoisomerase inhibitors.

HY-N15249

4"-Isovalerylspiramycin I Isovalerylspiramycin I; Shengjimycin E	Structural Classification Natural Products Microorganisms Source Classification	Topoisomerase DNA/RNA Synthesis Checkpoint Kinase (Chk) Apoptosis Bacterial
4"-Isovalerylspiramycin I (Isovalerylspiramycin I) is a topoisomerase 1 (TOP1) inhibitor and an antitumor agent. 4"-Isovalerylspiramycin I directly binds to TOP1, suppresses DNA replication, and induces DNA damage. 4"-Isovalerylspiramycin I downregulates phosphorylated CHEK1 and the ATR/CHEK1 DNA damage repair pathway, blocks DNA repair, and augments DNA damage. 4"-Isovalerylspiramycin I suppresses proliferation, migration, and invasion of osteosarcoma cells. 4"-Isovalerylspiramycin I induces apoptosis and cell cycle arrest in osteosarcoma cells. 4"-Isovalerylspiramycin I exerts antibacterial activity against methicillin-resistant Staphylococcus aureus. 4"-Isovalerylspiramycin I can be used for the research of osteosarcoma, upper respiratory bacterial infections, and methicillin-resistant Staphylococcus aureus infection .

HY-W800535

Cryptolepine	Malvaceae Structural Classification Alkaloids Sida acuta Burm. F. Quinoline Alkaloids Plants Indole Alkaloids Source Classification	NF-κB p38 MAPK mTOR Topoisomerase AMPK Apoptosis Cholinesterase (ChE) HIF/HIF Prolyl-Hydroxylase β-catenin
Cryptolepine is an orally active multi-potent alkaloid with anti-cancer, anti-bacterial, anti-viral, anti-malarial, anti-inflammatory, anti-hyperglycemic, relieve pain and other properties. Cryptolepine acts as an inhibitor of c-Myc, mTOR, NF-κB, HIF-1, MAPK and an activator of AMPKα1/2. It intercalates into DNA, inhibits topoisomerase II (Top II), disrupts mitochondrial dynamics and induces apoptosis. Cryptolepine also exhibits anti-plasmodial and cholinesterase inhibitory activities. Cryptolepine can be used in research related to tumors (melanoma, hepatocellular carcinoma, mammary adenocarcinoma, etc.), malaria, inflammatory diseases and diabetes, particularly in studies focused on inhibiting tumor growth and anti-plasmodial infection .

Cat. No.	Product Name	Chemical Structure

HY-B0268S1

Enoxacin-d8 hydrochloride

Enoxacin-d₈ (hydrochloride) is deuterium labeled Enoxacin. Enoxacin (AT 2266), a fluoroquinolone, interferes with DNA replication and inhibits bacterial DNA gyrase (IC₅₀=126 μg/ml) and topoisomerase IV (IC₅₀=26.5 μg/ml). Enoxacin is a miRNA processing activator and enhances siRNA-mediated mRNA degradation and promotes the biogenesis of endogenous miRNAs. Enoxacin has potent activities against gram-positive and -negative bacteria. Enoxacin is a cancer-specific growth inhibitor that acts by enhancing TAR RNA-binding protein 2 (TRBP)-mediated microRNA processing .

HY-10581AS

Gatifloxacin-d3 hydrochloride

Gatifloxacin-d₃ (hydrochloride) is the deuterium labeled Gatifloxacin (hydrochloride). Gatifloxacin hydrochloride (AM-1155; BMS-206584; PD135432) is a potent fluoroquinolone antibiotic with broad-spectrum antibacterial activity. Gatifloxacin hydrochloride inhibits bacterial type II topoisomerases (IC50=13.8 μg/ml for S. aureus topoisomerase IV) and E. coli DNA gyrase (IC50 = 0.109 μg/ml). Gatifloxacin hydrochloride can be used to treat bacterial conjunctivitis in vivo.

HY-W700069

Gatifloxacin-d4

Gatifloxacin-d₄ (AM-1155-d₄) is the deuterium labeled Gatifloxacin (HY-10581). Gatifloxacin (AM-1155; BMS-206584; PD135432) is a potent fluoroquinolone antibiotic with broad-spectrum antibacterial activity. Gatifloxacin inhibits bacterial type II topoisomerases (IC₅₀ = 13.8 μg/mL for S. aureus topoisomerase IV) and E.coli DNA gyrase (IC₅₀ = 0.109 μg/mL) . Gatifloxacin can be used for the study of bacterial conjunctivitis in vivo.

HY-B0330DS

(R)-Ofloxacin-d3

(R)-Ofloxacin-d₃ is the deuterium labeled (R)-Ofloxacin. (R)-Ofloxacin is the dextrorotatory enantiomer of Ofloxacin (HY-B0125) and is an orally effective fluoroquinolone antibiotic. (R)-Ofloxacin can inhibit the activity of bacterial DNA topoisomerase II, interfere with bacterial DNA replication and repair, and exert a bactericidal effect. (R)-Ofloxacin has a broad-spectrum antibacterial activity and has inhibitory effects on both Gram-negative and Gram-positive bacteria .

HY-B0268S2

Enoxacin-d8 hydrate

Enoxacin-d₈ (hydrate) is deuterium labeled Enoxacin. Enoxacin (AT 2266), a fluoroquinolone, interferes with DNA replication and inhibits bacterial DNA gyrase (IC₅₀=126 μg/ml) and topoisomerase IV (IC₅₀=26.5 μg/ml). Enoxacin is a miRNA processing activator and enhances siRNA-mediated mRNA degradation and promotes the biogenesis of endogenous miRNAs. Enoxacin has potent activities against gram-positive and -negative bacteria. Enoxacin is a cancer-specific growth inhibitor that acts by enhancing TAR RNA-binding protein 2 (TRBP)-mediated microRNA processing .

HY-B0506S1

Nadifloxacin-d5

Nadifloxacin-d₅ (OPC7251-d₅) is deuterium labeled Nadifloxacin (HY-B0506). Nadifloxacin (OPC7251) is a broad-spectrum quinolone antibiotic. Nadifloxacin inhibits bacterial DNA gyrase and topoisomerase IV, interfering with DNA replication. It also suppresses the production of proinflammatory cytokines (such as IL-1α, IL-6, and IL-8). Nadifloxacin exhibits antibacterial activity against various pathogens, including Propionibacterium acnes and Staphylococcus aureus. Nadifloxacin also exhibits anti-inflammatory activity. Nadifloxacin can be used in the research of skin infections such as acne vulgaris, folliculitis, and impetigo .

Targets Recommended: Bacterial

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-B0356G

Ciprofloxacin Bay-09867	Bacterial Topoisomerase Akt β-catenin	Inflammation/Immunology
Ciprofloxacin GMP is Ciprofloxacin (HY-B0356) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Ciprofloxacin (Bay-09867) is an orally active, blood-brain barrier permeable fluoroquinolone antibacterial agent. Ciprofloxacin exerts bactericidal effects primarily by inhibiting topoisomerase II and IV. Ciprofloxacin inhibits the proliferation of human dental pulp stem cells and chondrocytes from young rats, and also activates the Akt signaling pathway and upregulates markers such as β-catenin and Nanog to maintain the morphological characteristics of stem cells. Ciprofloxacin induces significant neurotoxicity and tissue damage, including reducing serotonin and glutathione levels in the brain, inducing oxidative stress and depression-like behaviors, and causing articular cartilage damage. Ciprofloxacin can be applied to research related to infections of necrotic young permanent teeth and neurotoxicity .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

bacterial topoisomerases

Inhibitors & Agonists

Fluorescent Dyes

Biochemical Assay Reagents

NaturalProducts

Isotope-Labeled Compounds

GMP Molecules

Natural
Products